Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002746 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00002746 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 24 participants.
The verdict
NCT00002746, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients with myelodysplastic syndrome.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1996-01 |
| Est. Completion | 2004-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002746
The ClinicalTrials.gov registry entry for NCT00002746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00002746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002746 about?
NCT00002746 is a clinical study titled "Interleukin-2 in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients with myelodysplastic syndrome.
What is the current status of trial NCT00002746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1996-01. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00002746?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002746?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.